Andrew Beelen

Title: The Innovative Contributions of Andrew Beelen

Introduction

Andrew Beelen is a notable inventor based in Research Triangle Park, NC (US). He has made significant contributions to the field of pharmaceuticals, particularly in cancer treatment. With a total of 3 patents, Beelen's work focuses on improving dosage regimes and reducing side effects in cancer therapies.

Latest Patents

One of Beelen's latest patents is titled "G1T38 superior dosage regimes." This invention outlines a human oral dosage regime for G1T38 that achieves a (mean AUC(0-24),ss (h*ng/mL))/(dose (mg)) ratio of less than 5. Additionally, it specifies a (mean AUC(0-24),ss (h*ng/mL))/(Absolute Neutrophil Count (cells/mm3)) ratio on day 22 of dosing that does not exceed 1.25. Another significant patent is focused on the "Treatment of EGFR-driven cancer with fewer side effects." This invention provides methods for treating EGFR-mutant cancer by administering a selective CDK4/6 inhibitor in combination with an EGFR-TKI. This approach aims to delay or reverse acquired resistance to previously administered EGFR-TKIs, enhancing treatment efficacy.

Career Highlights

Throughout his career, Andrew Beelen has worked with prominent companies such as G1 Therapeutics, Inc. and Pharmacosmos Holding A/S. His experience in these organizations has allowed him to develop innovative solutions that address critical challenges in cancer treatment.

Collaborations

Beelen has collaborated with talented individuals in the field, including Jay Copeland Strum and Jessica A. Sorrentino. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Andrew Beelen's innovative work in the pharmaceutical industry, particularly in cancer treatment, showcases his commitment to improving patient outcomes. His patents reflect a deep understanding of the complexities of cancer therapies and a dedication to reducing side effects.